[go: up one dir, main page]

WO2001003687A3 - Method and compositions for inhibiting biosynthesis or bioactivity of endogenous steroid sex hormones in humans - Google Patents

Method and compositions for inhibiting biosynthesis or bioactivity of endogenous steroid sex hormones in humans Download PDF

Info

Publication number
WO2001003687A3
WO2001003687A3 PCT/US2000/018909 US0018909W WO0103687A3 WO 2001003687 A3 WO2001003687 A3 WO 2001003687A3 US 0018909 W US0018909 W US 0018909W WO 0103687 A3 WO0103687 A3 WO 0103687A3
Authority
WO
WIPO (PCT)
Prior art keywords
bioactivity
sex hormones
humans
inhibiting biosynthesis
endogenous steroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/018909
Other languages
French (fr)
Other versions
WO2001003687A2 (en
Inventor
Claude L Hughes Jr
Denis A Magoffin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Priority to AU62097/00A priority Critical patent/AU6209700A/en
Publication of WO2001003687A2 publication Critical patent/WO2001003687A2/en
Publication of WO2001003687A3 publication Critical patent/WO2001003687A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed is a method of inhibiting biosynthesis or bioactivity of endogenous steroid sex hormones in both men and women involving the administration of a combination of phytosterol(s) and phytoestrogen(s) to inhibit enzymatic activity in the steroidogenic biosynthetic pathway that converts steroid progestins and androgens to more potent steroidal hormones, like estradiol and dihydrotestosterone. Also disclosed is a pharmaceutical composition useful for inhibiting biosynthesis or bioactivity of endogenous steroid sex hormones in humans. The pharmaceutical composition is formulated in a delivery system to deliver a dose of 50 to 250 mg of a phytosterol(s), such as campesterol, sitosterol, fucosterol, stigmasterol, stigmastanol, or stigmastadienone, or a derivative or conjugate of any of these, and 20 to 150 mg of a phytoestrogen(s), such as a lignan, isoflavone, flavone, or coumestan compound(s).
PCT/US2000/018909 1999-07-13 2000-07-12 Method and compositions for inhibiting biosynthesis or bioactivity of endogenous steroid sex hormones in humans Ceased WO2001003687A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU62097/00A AU6209700A (en) 1999-07-13 2000-07-12 Method and compositions for inhibiting biosynthesis or bioactivity of endogenoussteroid sex hormones in humans

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35300499A 1999-07-13 1999-07-13
US09/353,004 1999-07-13

Publications (2)

Publication Number Publication Date
WO2001003687A2 WO2001003687A2 (en) 2001-01-18
WO2001003687A3 true WO2001003687A3 (en) 2001-08-09

Family

ID=23387341

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/018909 Ceased WO2001003687A2 (en) 1999-07-13 2000-07-12 Method and compositions for inhibiting biosynthesis or bioactivity of endogenous steroid sex hormones in humans

Country Status (2)

Country Link
AU (1) AU6209700A (en)
WO (1) WO2001003687A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1190630A1 (en) * 2000-09-22 2002-03-27 Unilever N.V. Use of prenylated flavones
AU770436B2 (en) 2000-09-22 2004-02-19 Unilever Plc Use of prenylated flavones
WO2002074315A1 (en) * 2001-03-21 2002-09-26 Schering Aktiengesellschaft Pharmaceutical combined preparations containing aromatase inhibitors and substances having an estrogen effect in addition to the use thereof for producing a medicament for estrogen-replacement-therapy
PT1379146E (en) * 2001-03-23 2009-09-02 Nutricia Nv Preparation for the prevention and/or treatment of altered bone metabolism
US7736677B2 (en) * 2001-06-20 2010-06-15 Metaproteomics, Llc Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
US7361478B2 (en) 2001-11-20 2008-04-22 Allergan, Inc. High-throughput screen for identifying selective persistent sodium channels channel blockers
EP1360959A1 (en) * 2002-05-10 2003-11-12 Schering Aktiengesellschaft Use of 8-prenylflavanones for anti-angiogenesis therapy and for fibrinolytic therapy
EP1513955A2 (en) * 2002-05-28 2005-03-16 EVOTEC Neurosciences GmbH Diagnostic and therapeutic use of cyp11a1 for neurodegenerative diseases
FI20021184L (en) * 2002-06-19 2003-12-20 Hormos Nutraceutical Oy Ltd Lignan preparations
CN1791393A (en) * 2003-04-08 2006-06-21 麒麟麦酒株式会社 Composition for inhibition or prevention of bone density lowering and refreshment therefor
DE102007029042A1 (en) * 2007-06-21 2008-12-24 Analyticon Discovery Gmbh Pharmaceutical composition containing a trihydroxychromenone derivative
WO2009003838A2 (en) * 2007-07-05 2009-01-08 Unilever N.V. Composition comprising polyphenol
WO2009003832A2 (en) * 2007-07-05 2009-01-08 Unilever N.V. Composition comprising polyphenol
EP2025335A1 (en) * 2007-08-16 2009-02-18 InterMed Discovery GmbH Extracts with liver-X-receptor modulators, compounds and their use in weight control and treatment of disorders of lipid metabolism
FR2940123B1 (en) * 2008-12-22 2011-04-22 Granions Lab Des ASSOCIATION OF COMPOUNDS FOR THE TREATMENT OR PREVENTION OF HEAT BURSTS AND SUES BEEN GENERATED BY THE MENOPAUSE
JP2012092138A (en) * 2011-12-27 2012-05-17 Maruzen Pharmaceut Co Ltd Skin cosmetic and hair cosmetic
JP5668001B2 (en) * 2012-03-05 2015-02-12 丸善製薬株式会社 Skin cosmetics and hair cosmetics
US20140023618A1 (en) * 2012-07-23 2014-01-23 Applied Biology Systems and methods for treatment of androgenetic skin conditions by microbial organisms
CN106404955B (en) * 2016-09-10 2019-12-17 长治医学院 A method for measuring quercetin-7-glucoside content in sorghum red pigment
CN106822091A (en) * 2017-02-14 2017-06-13 天津中医药大学 Use of kaempferol in the preparation of medicines for preventing and/or treating diseases caused by excessive testosterone levels
IT201700027628A1 (en) * 2017-03-13 2018-09-13 Neilos S R L COMPOSITION FOR USE IN REDUCING PELI GROWTH
KR102020722B1 (en) * 2018-02-28 2019-09-11 전북대학교산학협력단 A composition comprising a combination of flavonoid and iridoid compound for treating and preventing androgen deficiency and PADAM syndrome
CN114984126A (en) * 2022-07-15 2022-09-02 深圳德荫堂生物科技有限公司 Biological agent suitable for supplementing hormone for female and production method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523087A (en) * 1995-02-15 1996-06-04 Bio-Virus Research Incorporated Pharmaceutical compositions for the treatment of diabetic male sexual dysfunction
WO1998021946A1 (en) * 1996-11-18 1998-05-28 Internutria, Inc. Composition and treatment for persistent reproductive transition symptoms

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523087A (en) * 1995-02-15 1996-06-04 Bio-Virus Research Incorporated Pharmaceutical compositions for the treatment of diabetic male sexual dysfunction
WO1998021946A1 (en) * 1996-11-18 1998-05-28 Internutria, Inc. Composition and treatment for persistent reproductive transition symptoms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S.A. GHANNUDI E.A.: "Adverse effects of phytoestrogens; I. Histological and histochemical effects of beta-sitosterol on the immature male rabbit.", THE LYBIAN JOURNAL OF SCIENCE, vol. 8b, 1978, pages 17 - 24, XP000979221 *

Also Published As

Publication number Publication date
WO2001003687A2 (en) 2001-01-18
AU6209700A (en) 2001-01-30

Similar Documents

Publication Publication Date Title
WO2001003687A3 (en) Method and compositions for inhibiting biosynthesis or bioactivity of endogenous steroid sex hormones in humans
NZ516502A (en) Administration of non-oral androgenic steroids to women having an elevated level of sex hormone binding globulin (SHBG)
BR9916579A (en) Three-phase oral contraceptive
WO1999063974A3 (en) Selective estrogen receptor modulator in combination with denydroepiandrosterone (dhea) or analogues
IE902458A1 (en) Method of treatment of androgen-related diseases
WO2007106264A3 (en) Extended cycle multiphasic oral contraceptive method
BR9710566A (en) Monophysical contraceptive method and a kit comprising a combination of a progestin and estrogen
ATE452641T1 (en) ORAL PHARMACEUTICAL COMPOSITION CONTAINING 15-HYDROXYTESTOSTERONE AND ITS DERIVATIVES
IL174893A (en) Triphasic estrogen contraceptive with low level initial estrogen phase followed by stepped increases in estrogen
EP0367576A2 (en) Estrogen nucleus derivatives for use in the inhibition of sex steroid activity
WO1999051271A3 (en) Compositions comprising glycol derivatives and alcohols
WO2006027745A3 (en) Trace elements
MXPA05001017A (en) COMPOSITION CONTAINING AN ANDROGENOUS 11beta-HALOGEN STEROID AND A PROGESTATIONAL HORMONE, AND MALE CONTRACEPTIVE BASED ON SAID COMPOSITION.
AU2002338277B2 (en) Estrogen replacement therapy
NZ334876A (en) Hormonal composition consisting of an estrogenic derivative and a progestative agent
WO1998004246A3 (en) Triphasic contraceptive method and kit comprising a combination of a progestin and estrogen
IL127923A0 (en) Oral contraceptive
WO2001040255A3 (en) 14,15-beta-methylene substituted androgens
CA2258177A1 (en) 19-nor-cholane steroids as neurochemical initiators of change in human hypothalamic function
PT921804E (en) BIPHASIC AND JOINT CONTRACEPTIVE METHOD ("KIT") COMPREHENDING A COMBINATION OF A PROGESTINE AND A STRTRENGTH
WO2005092441A3 (en) Extended cycle multiphasic oral contraceptive method
BR0014952A (en) Contraceptive medicine and its mode of preparation
BR0108411A (en) Male contraceptive formulation comprising norethisterone
WO1999045886A3 (en) New contraceptive kit for monotherapy
NZ536618A (en) An oily pharmaceutical composition for use as contraceptive and/or HRT comprising etonogesterel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP